Insulin Glargine: all 295 studies that test it
Page 2 of 3. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Insulin Glargine "All to Target" TrialCompletedNCT00384085Phase 4Results posted
- The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 DiabetesTerminatedNCT00366301Phase 4Results posted
- Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus InsulinCompletedNCT00338104Phase 4Results posted
- Perioperative Insulin Glargine Dosing StudyCompletedNCT00309465Phase 4Results posted
- Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory ControlTerminatedNCT00283049Phase 4Results posted
- Use of Insulin Glargine to Treat Diabetic KetoacidosisCompletedNCT00179127Not applicableResults posted
- The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)CompletedNCT00069784Phase 3Results posted
- Effect of Topical Insulin on Healing Rate of Pemphigus LesionsCompletedNCT07461103Phase 2
- Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver DiseaseActive, not recruitingNCT07274644Phase 4
- A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 DiabetesCompletedNCT06881264Phase 3
- Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in PakistanCompletedNCT06717191Phase 4
- Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in BangladeshCompletedNCT06674135Phase 4
- Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in MaliCompletedNCT06624943Phase 4
- A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)CompletedNCT06269107Phase 3
- Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness HyperglycemiaCompletedNCT06178874Not applicable
- Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic ControlCompletedNCT06107153Phase 3
- Early Administration of Insulin Glargine in Patients With Diabetic KetoacidosisTerminatedNCT06007508Phase 2
- Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL)CompletedNCT05780151Phase 4
- Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin TherapyStatus unknownNCT05545800Phase 3
- Outcome of Glargine Insulin in Renal Impairment Patients With Diabetic KetoacidosisStatus unknownNCT05219942Not applicable
- Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic DrugsCompletedNCT04980027Phase 4
- INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixiStatus unknownNCT04945070Phase 4
- Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 DiabetesStatus unknownNCT04893148Phase 4
- A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 DiabetesWithdrawnNCT04864977Phase 4
- Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.Status unknownNCT04664764Phase 4
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational DiabetesActive, not recruitingNCT04542148Phase 2
- Intensive Glycemic Control For Diabetic Foot Ulcer HealingStatus unknownNCT04323462Phase 4
- Effects of Local Insulin on Varicose Ulcers for Wound HealingCompletedNCT04310280Phase 3
- Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)CompletedNCT04196231Phase 4
- A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus PatientsCompletedNCT04101383Not applicable
- Effects of Insulin Glargine and Lixisenatide on the BrainTerminatedNCT03881995Phase 4
- Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes MellitusCompletedNCT03829891Not applicable
- Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal InsulinCompletedNCT03798080Phase 3
- Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)CompletedNCT03798054Phase 3
- Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of InsulinCompletedNCT03760991Phase 4
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)CompletedNCT03529123Phase 3
- Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mLCompletedNCT03406000Phase 4
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin TherapyCompletedNCT03359837Phase 4
- Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in RamadanTerminatedNCT03349840Phase 4
- Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)CompletedNCT03328845Phase 4
- Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixiCompletedNCT03130426Phase 3
- Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine DepartmentStatus unknownNCT03051243Phase 3
- Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin TreatmentCompletedNCT02967237Phase 4
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating InsulinCompletedNCT02967224Phase 4
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal InsulinCompletedNCT02967211Phase 4
- A Study Comparing Two Formulations of Insulin Glargine in Healthy ParticipantsCompletedNCT02955953Phase 1
- A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in TurkeyCompletedNCT02954692Phase 4
- Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic TherapyCompletedNCT02855684Phase 3
- Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)CompletedNCT02836704Phase 4
- Evaluation of Glycemic Changes During Exercise in Children With Type 1 DiabetesCompletedNCT02824510Not applicable
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in JapanCompletedNCT02752828Phase 3
- Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic DrugsCompletedNCT02752412Phase 3
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in JapanCompletedNCT02749890Phase 3
- Insulin in Total Parenteral NutritionCompletedNCT02706119Phase 4
- Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control After Acute StrokeStatus unknownNCT02607943Phase 3
- Treatment of Type 2 Diabetes With Long Acting Basal Insulin in JordanCompletedNCT02606357Phase 4
- Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 DiabetesTerminatedNCT02548494Not applicable
- Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)CompletedNCT02545842Phase 4
- Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 DiabetesStatus unknownNCT02526810Phase 4
- Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DMCompletedNCT02467920Phase 4
- Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus PatientsCompletedNCT02401243Phase 3
- A Comparison of Exenatide and Insulin GlargineCompletedNCT02325960Phase 4
- The Inova Type 2 Diabetes Mellitus StudyWithdrawnNCT02222623Not applicable
- Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN)CompletedNCT02216799Phase 4
- Feasibility Study to Determine the Optimal Calibration Method for Glucose SensorsCompletedNCT02155023Not applicable
- Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin TherapyWithdrawnNCT02144441Not applicable
- Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor TherapyCompletedNCT02027753Phase 4
- Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes MellitusCompletedNCT01868529Phase 1
- Cost Effectiveness of Glargine Insulin Versus NPH InsulinCompletedNCT01832935Phase 4
- A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy SubjectsCompletedNCT01809184Phase 1
- A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 DiabetesCompletedNCT01730014Phase 1
- A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin GlargineCompletedNCT01704417Phase 1
- Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT01689142Phase 3
- Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes MellitusCompletedNCT01689129Phase 3
- Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes MellitusCompletedNCT01676233Phase 1
- Insulin Therapy for Post-transplant Glucocorticoid Induced HyperglycemiaTerminatedNCT01648218Phase 4
- Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical WardsCompletedNCT01594060Phase 4
- Establishing Cardiovascular Biomarkers to Define Preferred Lantus® UseStatus unknownNCT01500850Phase 4
- Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 DiabetesCompletedNCT01497574Phase 1
- Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes MellitusCompletedNCT01493115Phase 1
- Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP AxisCompletedNCT01461616Phase 3
- Comparing Long-acting Insulins During Exercise in Type 1 DiabetesStatus unknownNCT01440439Phase 4
- Health Care for Type 1 Diabetes in Developing WorldCompletedNCT01424046Not applicable
- A Trial to Investigate Efficacy and Usability of Published Best Practice to Control GlycaemiaCompletedNCT01407289Phase 4
- Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DMCompletedNCT01357603Phase 1
- Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes MellitusCompletedNCT01349855Phase 1
- Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination TreatmentCompletedNCT01336751Phase 3
- Pharmacist Intervention for Glycemic Control in The CommunityCompletedNCT01335763Not applicable
- Study TO Prevent Diabetes With Short-term Insulin Glargine OnlyStatus unknownNCT01276912Not applicable
- Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM DiagnosisStatus unknownNCT01271517Phase 4
- JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic PatientsCompletedNCT01269996Phase 4
- Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 DiabetesCompletedNCT01249677Phase 4
- Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a DayCompletedNCT01234597Phase 4
- Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.CompletedNCT01223131Phase 3
- Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)CompletedNCT01212913Phase 4
- baSal BoluS Therapy in patIenTs With TypE 1 Diabetes MellitusCompletedNCT01204593Phase 4
- Apidra Children & Adolescents StudyCompletedNCT01202474Phase 4
- Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®CompletedNCT01195454Phase 1
- Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes MellitusCompletedNCT01169818Phase 4
- Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip TherapyCompletedNCT01153100Phase 1